EBOS GROUP LIMITED (EBO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBO

EBO - EBOS GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.68
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$34.20

24 Mar
2025

-0.780

OPEN

$34.66

-2.23%

HIGH

$34.66

37,302

LOW

$33.93

TARGET
$35.853 4.8% upside
Franking for last dividend paid out: 96%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL . SLA .
FNARENA'S MARKET CONSENSUS FORECASTS
EBO: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 141.3 137.1 xxx
DPS (cps) xxx N/A 107.3 xxx
EPS Growth xxx 6.3% - 3.0% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 24.5 xxx
Dividend Yield xxx N/A 3.2% xxx
Div Pay Ratio(%) xxx N/A 78.2% xxx

Dividend yield today if purchased 3 years ago: 1.55%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.66

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/08 - ex-div 49.71c (franking 49%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx141.3
DPS All xxxxxxxxxxxxxxx114.5
Sales/Revenue xxxxxxxxxxxxxxx13,189.1 M
Book Value Per Share xxxxxxxxxxxxxxx1,268.4
Net Operating Cash Flow xxxxxxxxxxxxxxx348.2 M
Net Profit Margin xxxxxxxxxxxxxxx2.06 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx11.12 %
Return on Invested Capital xxxxxxxxxxxxxxx7.88 %
Return on Assets xxxxxxxxxxxxxxx4.12 %
Return on Equity xxxxxxxxxxxxxxx11.12 %
Return on Total Capital xxxxxxxxxxxxxxx12.64 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx96.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx823 M
Long Term Debt xxxxxxxxxxxxxxx820 M
Total Debt xxxxxxxxxxxxxxx1,643 M
Goodwill - Gross xxxxxxxxxxxxxxx2,068 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx217 M
Price To Book Value xxxxxxxxxxxxxxx2.32

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx118.8 M
Capex % of Sales xxxxxxxxxxxxxxx0.90 %
Cost of Goods Sold xxxxxxxxxxxxxxx12,232 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx474 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx89 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.4

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

5

xxxxxxxxx xx xxxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

20/02/2025

2

Downgrade to Accumulate from Buy

$37.00

8.19%

Ebos Group produced a first half result that was in line with forecasts. Ord Minnett observes the business is executing well on its revenue and cost initiatives and now forecasts FY25 EBITDA of $592m and net profit of $269m.

The business is "quality", the broker adds and should emerge from the transition period in FY25 with a well-established and diversified business model. Target rises to $37.00 from $35.50. Rating pulls back to Accumulate from Buy after the recent re-rating.

FORECAST
Ord Minnett forecasts a full year FY25 dividend of 107.30 cents and EPS of 137.40 cents.
Ord Minnett forecasts a full year FY26 dividend of 118.80 cents and EPS of 158.40 cents.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

24/03/2025

2

Overweight

-

-

Jarden highlights the Australian government's proposal to significantly reduce the costs of medicines on the Pharmaceutical Benefits Scheme could benefit Ebos Group via improved volumes.

The broker notes script volumes on a per capita basis have been flat to lower for a while, with growth driven by a higher average price per script. The volume story could change with the new proposal which the Opposition also intends to match.

One risk is an offsetting reduction in price if the government shares the higher funding responsibility with manufacturers, the broker cautions.

Target price of NZ$41.50 and Overweight rating retained.

FORECAST
Jarden forecasts a full year FY25 dividend of 107.00 cents and EPS of 141.00 cents.
Jarden forecasts a full year FY26 dividend of 111.00 cents and EPS of 159.00 cents.
Access Extra Coverage Research History >

EBO STOCK CHART

FNArena News on EBO

1
Australian Broker Call *Extra* Edition – Feb 24, 2025

Feb 24 2025 - Daily Market Reports
2
Weekly Ratings, Targets, Forecast Changes – 21-02-25

Feb 24 2025 - Weekly Reports
3
FNArena Corporate Results Monitor – 22-02-2025

Feb 22 2025 - Australia
4
Rudi’s View: Best Ideas & Conviction Calls

Feb 20 2025 - Rudi's View
5
FNArena Corporate Results Monitor – 20-02-2025

Feb 20 2025 - Australia

Latest Healthcare services News

1
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
2
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
3
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
4
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
5
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
6
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
7
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
8
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
9
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
10
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps